Danske Bank A S Takes $9.94 Million Position in United Therapeutics Corporation $UTHR

Danske Bank A S bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 18,349 shares of the biotechnology company’s stock, valued at approximately $9,942,000.

Several other large investors have also recently modified their holdings of the stock. Leuthold Group LLC grew its position in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after acquiring an additional 3,126 shares during the last quarter. UBS Group AG boosted its stake in shares of United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after purchasing an additional 70,445 shares during the period. Nicholas Investment Partners LP boosted its stake in shares of United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after purchasing an additional 3,766 shares during the period. M&T Bank Corp grew its holdings in shares of United Therapeutics by 171.6% in the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after purchasing an additional 1,985 shares during the last quarter. Finally, Seven Fleet Capital Management LP bought a new position in shares of United Therapeutics in the fourth quarter worth about $633,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $513.12 on Friday. The firm has a market capitalization of $22.01 billion, a P/E ratio of 18.36, a P/E/G ratio of 1.76 and a beta of 0.59. The business’s 50-day moving average is $533.08 and its 200 day moving average is $537.36. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period last year, the business earned $6.41 EPS. United Therapeutics’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Morgan Stanley set a $515.00 price target on United Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 442,575 shares of company stock worth $239,326,330. 8.60% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.